LEXINGTON — Synta Pharmaceuticals Corp. said yesterday its fourth-quarter loss widened on a drop in revenue and a slight boost in expenses.
The company lost $8.8 million, or 21 cents per share, compared with a loss of $7 million, or 21 cents per share. Synta had about 7.3 million additional shares of stock outstanding during the most recent period. Revenue fell to $4 million from $4.7 million.
Analysts polled by FactSet expected a loss of 23 cents per share on $4 million in revenue.
Operating expenses rose 6 percent to $12.4 million.
For the full year, the company lost $37.5 million, or 93 cents per share, compared with profit of $79.1 million, or $2.32 per share, in 2009, when it received a hefty payment from its former partner GlaxoSmithKline.